ASCO Genitourinary Cancers Symposium

 

ASCO Genitourinary Cancers Symposium
D

ASCO GU 2022: An AI-Derived Digital Pathology-Based Biomarker to Predict the Benefit of ADT in Localized Prostate Cancer With Validation in NRG/RTOG 9408

By ASCO Genitourinary Cancers Symposium FEATURING Daniel Spratt
By ASCO Genitourinary Cancers Symposium FEATURING Daniel Spratt
33 views
March 14, 2022
0 Comments
Login to view comments. Click here to Login

Featured Video

20:59
Exelixis

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam

Featured Video

20:25
Exelixis

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam
Videos
08:55
ASCO Genitourinary Cancers Symposium

ASCO GU 2022: Community Oncologists’ Perceptions of and Barriers to …

Feat. A. Gajra
09:36
ASCO Genitourinary Cancers Symposium

ASCO GU 2022 on EV-103 Cohort H: Antitumor Activity of Neoadjuvant T…

Feat. N. Mar
08:54
ASCO Genitourinary Cancers Symposium

Trials in Progress in Neoadjuvant Systemic Therapy in MIBC

Feat. P. Grivas
11:23
ASCO Genitourinary Cancers Symposium

ASCO GU 2022: An AI-Derived Digital Pathology-Based Biomarker to Pre…

Feat. D. Spratt
12:14
ASCO Genitourinary Cancers Symposium

ASCO GU 2022 Update on CheckMate 214 With Extended 5-Year Follow-Up:…

Feat. S. Tykodi
06:52
ASCO Genitourinary Cancers Symposium

ASCO GU 2022: Tumor Mutational Burden as a Predictive Biomarker for …

Feat. S. Gupta
20:27
ASCO Genitourinary Cancers Symposium

ASCO GU 2022 on Radiation Therapy in Localized Prostate Cancer: Chan…

Feat. A. Bossi
13:49
ASCO Genitourinary Cancers Symposium

ASCO GU 2022 on Multi-Institutional Matched Comparison of Radical Cy…

Feat. A. Zlotta
09:54
ASCO Genitourinary Cancers Symposium

ASCO GU 2022 Updates on the Randomized Meet-URO12 Trial: Niraparib +…

Feat. M. Di Maio
04:06
ASCO Genitourinary Cancers Symposium

ASCO GU 2022 Updates on the Phase 3 TITAN Study: The Effect of Prior…

Feat. K. Chi
10:53
ASCO Genitourinary Cancers Symposium

ASCO GU 2022 TROPHY-U-01 Cohort 3: Sacituzumab Govitecan + Pembroliz…

Feat. P. Grivas
05:41
Fred Saad

ARASENS Trial Updates: OS With Darolutamide vs. Placebo in Combinati…

11:45
ASCO Genitourinary Cancers Symposium

ASCO GU 2022 PROpel Phase III Trial Highlights: Olaparib & Abira…

Feat. F. Saad
08:02
ASCO Genitourinary Cancers Symposium

ASCO GU 2022 Updates on the ARIES Trial: 1L Avelumab in PD-L1+ Meta…

Feat. R. Iacovelli
11:11
ASCO Genitourinary Cancers Symposium

ASCO GU 2022 on a Study EV-103 Cohort H: Antitumor Activity of Neoad…

Feat. D. Petrylak
07:47
ASCO Genitourinary Cancers Symposium

ASCO GU 2022 on a Phase II Study of Nivo + Ipi for Advanced GU Malig…

Feat. B. McGregor
11:32
ASCO Genitourinary Cancers Symposium

ASCO GU 2022: Phase II/III Clinical Results of IL-15RαFc Superagonis…

Feat. S. Chang
10:01
ASCO Genitourinary Cancers Symposium

ASCO GU 2022 on Management of Toxicities With Novel Systemic Therapi…

Feat. T. Flaig
07:12
ASCO Genitourinary Cancers Symposium

ASCO GU 2022 on Bone Mineral Density in De Novo mCSPC Treated With/W…

Feat. G. Roubaud
08:35
ASCO Genitourinary Cancers Symposium

ASCO GU 2022 on 1L Axitinib + Pembro in Advanced RCC: Real-World Tre…

Feat. Y. Zakharia
04:01
ASCO Genitourinary Cancers Symposium

ASCO GU 2022 on Nivo + Cabo vs. Sunitinib for Advanced RCC: Final OS…

Feat. T. Powles
05:00
ASCO Genitourinary Cancers Symposium

ASCO GU 2022 OS in mHSPC Treated With Enzalutamide + ADT by High/Low…

Feat. A. Armstrong
06:48
ASCO Genitourinary Cancers Symposium

ASCO GU 2022 CABOSEQ Trial Updates on the Efficacy of Cabozantinib P…

Feat. V. Navani
08:33
ASCO Genitourinary Cancers Symposium

ASCO GU 2022 on the Immune Profiling of Advanced Prostate Cancer Har…

Feat. M. Soleimani
05:43
ASCO Genitourinary Cancers Symposium

ASCO GU 2022: A Phase I/II Study of Nivo & Axitinib in Patients …

Feat. M. Zibelman
06:49
ASCO Genitourinary Cancers Symposium

ASCO GU 2022 on Gem & Cis as Neoadjuvant Chemo in High-Grade UTU…

Feat. W. Yip
16:00
ASCO Genitourinary Cancers Symposium

ASCO GU 2022 Germline Mutations of Interests in Renal Cell Carcinoma

Feat. M. Dean
07:40
ASCO Genitourinary Cancers Symposium

ASCO GU 2022 on Futibatinib + Pembro in Advanced/Metastatic UC: Prel…

Feat. V. Koshkin
09:23
ASCO Genitourinary Cancers Symposium

ASCO GU 2022 on Molecular Alterations Across Sites of Metastasis in …

Feat. R. McKay
07:53
ASCO Genitourinary Cancers Symposium

ASCO GU 2022 Updates on Neoadjuvant Cabozantinib in Locally Advanced…

Feat. M. Bilen
06:58
ASCO Genitourinary Cancers Symposium

ASCO GU 2022 on the Updated OS Analysis for Docetaxel +/- Capivasert…

Feat. S. Crabb
11:54
ASCO Genitourinary Cancers Symposium

ASCO GU 2022 Efficacy & Safety of Continuing Enza in Chemo-Naïve…

Feat. A. Merseburger
03:02
ASCO Genitourinary Cancers Symposium

ASCO GU 2022 on Pembro as Post-Nephrectomy Adjuvant Therapy for RCC:…

Feat. T. Choueiri
07:45
ASCO Genitourinary Cancers Symposium

ASCO GU 2022 on Cabozantinib in Advanced RCC After the Failure of CP…

Feat. V. Grünwald
13:17
ASCO Genitourinary Cancers Symposium

ASCO GU 2022 Highlights on the ADCs in Advanced Urothelial Cancer: C…

Feat. S. Tagawa
05:16
ASCO Genitourinary Cancers Symposium

ASCO GU 2022 Survival Outcomes and Characterization of Patients With…

Feat. N. Sayegh
16:34
ASCO Genitourinary Cancers Symposium

ASCO GU 2022 Highlights on Adjuvant and Consolidative Therapy in Oli…

Feat. N. Haas